<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78909">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01877746</url>
  </required_header>
  <id_info>
    <org_study_id>ICRC-ICIT-01</org_study_id>
    <nct_id>NCT01877746</nct_id>
  </id_info>
  <brief_title>CZECH-ICIT (CZECH Inflammatory Cardiomyopathy Immunosuppression Trial)</brief_title>
  <official_title>RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESSIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATHY IMMUNOSUPPRESSION TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anne's University Hospital Brno, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Anne's University Hospital Brno, Czech Republic</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effect of combined immunosuppressive therapy given
      on the top standard medical therapy of chronic heart failure according to current guidelines
      with standard medical therapy of chronic heart failure alone in patients with infammatory
      cardiomyopathy (ICM).

      Suitable subjects are characterized by EMB established presence of myocardial inflammation /
      negative polymerase chain reaction assay (PCR) findings of cardiotropic infectious agents
      and with varying duration of heart failure symptoms and left ventricular (LV) systolic
      dysfunction (phase A).

      Further, to compare the effect of two regimens of combined immunosuppressive therapy in
      these patients with ICM (phase B).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>comparison of the change in LV ejection fraction</measure>
    <time_frame>baseline and in 12 months after the initiation of immunosuppressive therapy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of the change of LV end-diastolic and end-systolic diameters</measure>
    <time_frame>baseline and in 12 months after the initiation of immunosuppressive therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of the change of New York Heart Association (NYHA) class</measure>
    <time_frame>baseline and in 12 months after the initiation of immunosuppressive therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of total mortality</measure>
    <time_frame>baseline and in 12 months after the initiation of immunosuppressive therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of the combined end-point</measure>
    <time_frame>baseline and in 12 months after the initiation of immunosuppressive therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>combined end-point (death from cardiac reasons, heart transplantation, hospitalization for heart failure, successful resuscitation for cardiac arrest and adequate implantable cardioverter-defibrillator (ICD) shock for ventricular tachycardia or fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of the change in the number of infiltrating inflammatory cells in EMB</measure>
    <time_frame>baseline and in 12 months after the initiation of immunosuppressive therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Inflammatory Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>R1 - combined immunosuppressive therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>application of the combined immunosuppressive therapy in the first dosing regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2 - combined immunosuppressive therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>application of the combined immunosuppressive therapy in the second dosing regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S - standard therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>only standard medical therapy of chronic heart failure without application of the combined immunosuppressive therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of prednisone and azathioprine</intervention_name>
    <description>Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.
Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.</description>
    <arm_group_label>R1 - combined immunosuppressive therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of prednisone and azathioprine</intervention_name>
    <description>Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.
Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.</description>
    <arm_group_label>R2 - combined immunosuppressive therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention, only standard medical therapy</description>
    <arm_group_label>S - standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females aged 18 to 65 years at the time of signing the informed consent

          2. Signing of the informed consent.

          3. LV systolic dysfunction defined by ejection fraction less than/or equal 40% as
             assessed by echocardiography and symptoms of  heart failure (minimum NYHA class II)
             lasting for at least 2 weeks at the time of randomization. This criterion also
             determines the inclusion of the study subjects in one of two substudies (CZECH-ICIT 1
             or CZECH-ICIT 2).

               -  LV systolic dysfunction (defined by ejection fraction less than/or equal 40%)
                  and symptoms of  heart failure (minimum NYHA class II) lasting 2 weeks to 6
                  months, with standard medical therapy of chronic heart failure given for at
                  least 2 weeks - the subject fulfills criterion for inclusion in CZECH-ICIT 1
                  substudy

               -  LV systolic dysfunction (defined by ejection fraction less than/or equal 40%)
                  and symptoms of  heart failure (minimum NYHA class II) lasting more than 6
                  months, with standard medical therapy of chronic heart failure given for at
                  least 2 weeks - the subject fulfills criterion for inclusion in CZECH-ICIT 2
                  substudy

          4. Positive immunohistochemistry finding of myocardial inflammation in endomyocardial
             biopsy (EMB). EMB must have been be performed no more than 6 weeks prior to the
             inclusion in the study. Positive immunohistochemistry EMB finding demonstrating
             myocardial inflammation is defined by the presence of at least 7/mm2 cluster of
             differentiation 3 (CD3) positive lymphocytes and/or at least 14 infiltrating
             leucocytes (LCA+ cells)/mm2 in the specimen.

          5. The absence of infectious agent in EMB is defined by negative results of PCR testing
             of EMB specimens. PCR testing will be aimed to exclude the presence of enteroviruses
             (ECHO, coxsackie), adenoviruses, herpes viruses (herpes simplex virus (HSV-1),
             Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpes virus (HHV-6)),
             Borrelia burgdorferi and parvovirus B19. In the case of parvovirus B19, a negative
             PCR result will be considered when less than 500 viral copies/ug genomic DNA are
             detected. EMB must have been performed no more than 6 weeks prior to the inclusion in
             the study.

          6. Negative blood pregnancy test in fertile females.

          7. Usage of the effective method of contraception (hormonal or 2 barrier method of
             contraception)

        Exclusion Criteria:

          1. The presence of coronary artery disease, defined by angiographic findings of one or
             more coronary artery stenosis &gt; 50%, history of previous myocardial infarction and/or
             percutaneous or surgical myocardial revascularization. Coronary angiography must not
             have been performed more than 2 years before randomization into the study.

          2. Permanent pacemaker including cardiac resynchronization therapy.

          3. The presence of uncontrolled, persistent supraventricular tachyarrhythmia, with
             ventricular rate &gt; 120/min, lasting more than 1 week before EMB.

          4. The presence of uncontrolled arterial hypertension, defined by blood pressure values
             &gt; 180mmHg (for systolic pressure) and/or 110mmHg (for diastolic pressure) lasting
             more than 3 months.

          5. The presence of at least moderately hemodynamically significant primary valvulopathy
             or congenital heart disease (apart from patent foramen ovale and non-significant
             atrial septal defect).

          6. Previous heart valve surgery (replacement or reconstruction) or surgical correction
             of congenital heart disease. adu.

          7. A history of cytostatic therapy or radiotherapy.

          8. Alcoholism defined as ethanol intake &gt;90 g/day.

          9. The presence of uncontrolled endocrine of metabolic disorder.

         10. Gravidity and lactation.

         11. Known hypersensitivity to investigational drugs.

         12. All contraindications of immunosuppressive therapy according to Summary of product
             characteristics (SmPC) of both investigational medicinal products: untreated systemic
             infection, poorly manageable diabetes mellitus, osteoporosis, florid gastric or
             duodenal ulcer, uncontrolled arterial hypertension, history of malignant disease with
             oncological treatment finished less than 5 years, proven immunodeficiency, renal of
             hepatic insufficiency (serum creatinine &gt; 200 Âµmol/l; alanine aminotransferase (ALT)
             and/or aspartate aminotransferase (AST) activity greater than three times the
             standard), leukocytopenia (leucocytes less than 4 x 10 9/l), thrombocytopenia
             (platelets less than 100 x 10 9/l), anemia (hemoglobin concentration  less than 100
             g/l).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Krejci, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>employee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomas Palecek, Assoc. prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>without affiliation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Anne`s University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Krejci, MD, Ph.D</last_name>
      <phone>543 182 405</phone>
      <phone_ext>00420</phone_ext>
      <email>jan.krejci@fnusa.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Krejci, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General University hospital in Prague</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Palecek, Assoc. professor</last_name>
      <phone>224 962 634</phone>
      <phone_ext>00420</phone_ext>
      <email>tpalec@lf1.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Tomas Palecek, Assoc. prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001 Jul 3;104(1):39-45.</citation>
    <PMID>11435335</PMID>
  </reference>
  <reference>
    <citation>Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009 Aug;30(16):1995-2002. doi: 10.1093/eurheartj/ehp249. Epub 2009 Jun 25.</citation>
    <PMID>19556262</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 11, 2013</lastchanged_date>
  <firstreceived_date>June 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Anne's University Hospital Brno, Czech Republic</investigator_affiliation>
    <investigator_full_name>Jan Krejci, MD, Ph.D</investigator_full_name>
    <investigator_title>MD, Ph.D</investigator_title>
  </responsible_party>
  <keyword>ICM</keyword>
  <keyword>myocarditis</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>endomyocardial biopsy</keyword>
  <keyword>immunosuppression</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
